Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Strides Pharma Science is a pharmaceutical formulations company focused on finished-dosage generics — with a specialization in soft gelatin capsules and other complex oral forms — selling primarily in the US and other regulated markets, plus emerging markets. It follows a B2B-plus-own-front-end model in the US. Its bio/CDMO arm OneSource Specialty Pharma was demerged and separately listed, leaving Strides focused on the regulated-market generics business.
Strides Pharma Science Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Strides Pharma Science Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 60.34 | 390.54 | -7.76 |
| Book value / share (₹) | 341.68 | 280.64 | 225.43 |
| Return on equity | 17.7% | 138.9% | -3.4% |
| Return on capital employed | 17.9% | 17.7% | 17.6% |
| Operating margin | 14.9% | 13.4% | 12.9% |
| Net margin | 11.8% | 78.8% | -2.3% |
| EBITDA | ₹925 Cr | ₹803 Cr | ₹743 Cr |
| Free cash flow | ₹280 Cr | ₹442 Cr | ₹583 Cr |
| Total debt | ₹1,669 Cr | ₹1,796 Cr | ₹2,415 Cr |
| Debt to equity | 0.53 | 0.69 | 1.17 |
| Interest coverage | 4.0 | 2.5 | 1.7 |
| Current ratio | 1.25 | 1.20 | 1.03 |
| Shares outstanding | 9,21,73,000 | 9,21,63,000 | 9,19,00,000 |
Open the full income statement, balance sheet and cash flow for STAR →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.